Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi
Background: Malawi switched from protease inhibitor- (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based paediatric first- and second-line antiretroviral therapy (ART) regimens to dolutegravir-based regimens (DBR) in 2020. By 2022, over 98% of children living with HIV (CLHIV) were on DBR, requiring monitoring of dolutegravir (DTG) resistance. We evaluated the prevalence and patterns of drug resistance…